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Abstract
Räsänen Pirjo. Routine Measurement of Health-Related Quality of Life in Assessing 
Cost-effectiveness in Secondary Health Care. STAKES, Research Report 163. 
Helsinki, Finland, 2007. ISBN 978-951-33-1981-6
Aims: The aims of this study were 1) to identify and describe health economic 
studies that have used quality-adjusted life years (QALYs) based on actual 
measurements of patients’ health-related quality of life (HRQoL); 2) to test the 
feasibility of routine collection of health-related quality of life (HRQoL) data as an 
indicator of effectiveness of secondary health care; and 3) to establish and compare 
the cost-utility of three large-volume surgical procedures in a real-world setting 
in the Helsinki University Central Hospital, a large referral hospital providing 
secondary and tertiary health-care services for a population of approximately 1.4 
million.
Patients and methods: So as to identify studies that have used QALYs as an 
outcome measure, a systematic search of the literature was performed using the 
Medline, Embase, CINAHL, SCI and Cochrane Library electronic databases. Initial 
screening of the identified articles involved two reviewers independently reading 
the abstracts; the full-text articles were also evaluated independently by two 
reviewers, with a third reviewer used in cases where the two reviewers could not 
agree a consensus on which articles should be included.
The feasibility of routinely evaluating the cost-effectiveness of secondary health 
care was tested by setting up a system for collecting HRQoL data on approximately 
4 900 patients’ HRQoL before and after operative treatments performed in the 
hospital. The HRQoL data used as an indicator of treatment effectiveness was 
combined with diagnostic and financial indicators routinely collected in the 
hospital.
To compare the cost-effectiveness of three surgical interventions, 712 patients 
admitted for routine operative treatment completed the 15D HRQoL questionnaire 
before and also 3–12 months after the operation. QALYs were calculated using 
the obtained utility data and expected remaining life years of the patients. Direct 
hospital costs were obtained from the clinical patient administration database of 
the hospital and a cost-utility analysis was performed from the perspective of the 
provider of secondary health care services.
Main results: The systematic review (Study I) showed that although QALYs gained 
are considered an important measure of the effectiveness of health care, the number 
of studies in which QALYs are based on actual measurements of patients’ HRQoL 
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is still fairly limited. Of the reviewed full-text articles, only 70 reported QALYs 
based on actual before–after measurements using a valid HRQoL instrument.
Collection of simple cost-effectiveness data in secondary health care is feasible 
and could easily be expanded and performed on a routine basis (Study II). It allows 
meaningful comparisons between various treatments and provides a means for 
allocating limited health care resources.
The cost per QALY gained was €2 770 for cervical operations and €1 740 for 
lumbar operations. In cases where surgery was delayed the cost per QALY was 
doubled (Study III).
The cost per QALY ranges between subgroups in cataract surgery (Study IV). 
The cost per QALY gained was €5 130 for patients having both eyes operated on 
and €8 210 for patients with only one eye operated on during the 6-month follow-
up. In patients whose first eye had been operated on previous to the study period, 
the mean HRQoL deteriorated after surgery, thus precluding the establishment of 
the cost per QALY.
In arthroplasty patients (Study V) the mean cost per QALY gained in a one-
year period was €6 710 for primary hip replacement, €52 270 for revision hip 
replacement, and €14 000 for primary knee replacement.
Conclusions: Although the importance of cost-utility analyses has during recent 
years been stressed, there are only a limited number of studies in which the 
evaluation is based on patients’ own assessment of the treatment effectiveness. 
Most of the cost-effectiveness and cost-utility analyses are based on modeling 
that employs expert opinion regarding the outcome of treatment, not on patient-
derived assessments.
Routine collection of effectiveness information from patients entering 
treatment in secondary health care turned out to be easy enough and did not, for 
instance, require additional personnel on the wards in which the study was executed. 
The mean patient response rate was more than 70 %, suggesting that patients were 
happy to participate and appreciated the fact that the hospital showed an interest 
in their well-being even after the actual treatment episode had ended.
Spinal surgery leads to a statistically significant and clinically important 
improvement in HRQoL. The cost per QALY gained was reasonable, at less than 
half of that observed for instance for hip replacement surgery. However, prolonged 
waiting for an operation approximately doubled the cost per QALY gained from 
the surgical intervention.
The mean utility gain following routine cataract surgery in a real world 
setting was relatively small and confined mostly to patients who had had both 
eyes operated on. The cost of cataract surgery per QALY gained was higher than 
previously reported and was associated with considerable degree of uncertainty.
Hip and knee replacement both improve HRQoL. The cost per QALY gained 
from knee replacement is two-fold compared to hip replacement.
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Cost-utility results from the three studied specialties showed that there is great 
variation in the cost-utility of surgical interventions performed in a real-world 
setting even when only common, widely accepted interventions are considered. 
However, the cost per QALY of all the studied interventions, except for revision 
hip arthroplasty, was well below €50 000, this figure being sometimes cited in the 
literature as a threshold level for the cost-effectiveness of an intervention.
Based on the present study it may be concluded that routine evaluation of the 
cost-utility of secondary health care is feasible and produces information essential 
for a rational and balanced allocation of scarce health care resources.
Key words: cataract, cervical spine, cost-effectiveness, cost-utility analysis, hip 
replacement, health-related quality of life, knee replacement, lumbar spine, quality-
adjusted life year, secondary health care
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Summary in Finnish
Räsänen Pirjo. Routine Measurement of Health-Related Quality of Life in Asses-
sing Cost-effectiveness in Secondary Health Care [Terveyteen liittyvä elämänlaatu 
erikoissairaanhoidon kustannusvaikuttavuuden arvioinnissa]. STAKES, Research 
Report 163. Helsinki, Finland 2007. ISBN 978-951-33-1981-6
Järjestelmällisesti kerätty tieto hoidon vaikuttavuudesta ja kustannusvaikuttavuu-
desta on keskeisessä asemassa, kun erikoissairaanhoidon palveluja järjestetään tu-
levaisuudessa. Rajalliset resurssit ja terveysteknologioiden nopea kehittyminen 
edellyttävät toimintojen arviointia ja priorisointia. Päätösten tulee olla läpinäkyviä 
ja perustua tutkittuun tietoon, mutta ennen kaikkea myös siihen, miten potilaat it-
se kokevat hyötyvänsä erikoissairaanhoidon toiminnoista.
Tämän väitöskirjan tavoitteena oli kartoittaa tutkimukset, joissa hoidon lop-
putulosta arvioitiin laatupainotteisina elinvuosina siten, että hoidon arvioijana oli 
potilas itse. Lisäksi väitöskirjan tavoitteena oli tutkia, miten erikoissairaanhoidon 
kustannusvaikuttavuuden arviointia voitaisiin toteuttaa Helsingin ja Uudenmaan 
sairaanhoitopiirissä. Erikoissairaanhoidon kustannusvaikuttavuuden arvioimisek-
si tutkimukseen valittiin kolme lääketieteen erikoisalaa, jotka edustavat volyymil-
taan suuria erikoissairaanhoidon ryhmiä, ja joilla siten on vaikutusta sekä kansan-
talouteen että kansanterveyteen.
Taloudellisten arviointien määrä terveydenhuollossa on kasvanut viimeisen 
kahden vuosikymmenen ajan. Tästä huolimatta kirjallisuuskatsauksemme perus-
teella löytyi vain vähän tutkimuksia, joissa hoidon lopputulosmittarina ovat laatu-
painotteiset elinvuodet, QALYt (Quality-adjusted life years) siten, että arvio hoi-
don vaikuttavuudesta on kysytty validilla menetelmällä potilaalta itseltään.
Hoidon vaikuttavuutta mitattiin 712 kirurgisesti hoidetun potilaan antamal-
la arviolla terveyteen liittyvästä elämänladusta ennen hoitoa ja noin 3–12 kuukau-
den kuluttua hoidosta. Terveyteen liittyvän elämänlaadun mittarina oli Suomessa 
kehitetty geneerinen, potilaan itsensä täyttämä 15D- kyselylomake. Kaikki potilaat 
saivat erikoissairaanhoidon normaalikäytännön mukaista hoitoa. Vaikuttavuustie-
to yhdistettiin hoidon kustannuksia ja järjestämistä koskevaan tietoon hoidon kus-
tannusvaikuttavuuden arvioimiseksi.
Vaikuttavuustiedon rutiininomainen kerääminen erikoissairaanhoitoon tule-
vilta potilaita osoittautui kohtuullisen helpoksi eikä vaatinut esimerkiksi lisähenki-
löstön palkkaamista osastoille, joilla tutkimus toteutettiin. Vastusprosentti oli kes-
kimäärin yli 70 prosenttia, mikä osoittaa sen, että potilaat osallistuvat mielellään 
tutkimukseen ja arvostavat sitä, että heidän voinnistaan ollaan kiinnostuneita vie-
lä hoidon päättymisen jälkeenkin.
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Tutkimustulosten mukaan sekä polvi- ja lonkkaproteesipotilaiden että lanne- 
ja kaularangan ahtaumapotilaiden terveyteen liittyvä elämänlaatu paranee seu-
ranta-aikana merkitsevästi. Lonkan uusintaleikkaus- ja kaihileikkauspotilaiden 
elämänlaadussa paranemista tapahtuu vain vähän. Erikoissairaanhoidolle aiheutu-
neet kustannukset potilasta kohden vaihtelivat 1 640 € (kaihikirurgia) ja 11 240 € 
(lonkan uusintaproteesileikkaus) välillä. Kustannukset laatupainotteista elinvuot-
ta kohden olivat halvimmat lannerangan ahtaumapotilailla, 1 740 €, ja kalleimmat 
lonkan uusintaproteesileikkauksessa, 52 270 €.
Johtopäätöksenä voidaan todeta että järjestelmällinen ja rutiininomaisesti to-
teutettu vaikuttavuustiedon kerääminen ja yhdistäminen kustannustietoihin on 
mahdollista melko vähäisin ponnistuksin. Tutkimus osoitti, että eri potilasryhmi-
en kustannus laatupainotteista elinvuotta kohden vaihtelee suuresti, mutta on kai-
kissa muissa ryhmissä paitsi lonkan uusintaproteesileikkauksessa alle 50 000 €, jota 
alan kirjallisuudessa pidetään eräänlaisena kustannusvaikuttavan hoidon katto-
hintana. Laatupainotteiset elinvuodet ovat tärkeä terveydenhuollon vaikuttavuu-
den mittari. Arviointien, joissa laatupainotteiset elinvuodet perustuvat potilaiden 
itsensä antamaan arvioon saamastaan hoidosta ennen–jälkeen-asetelmassa, tulisi 
olla yksi keskeinen menetelmä pyrittäessä kustannusvaikuttavaan erikoissairaan-
hoitoon.
Avainsanat: kaihi, kaularanka, kustannusvaikuttavuus, kustannus-utiliteettiana-
lyysi, lonkkaproteesi, terveyteen liittyvä elämänlaatu, polviproteesi, lanneselkä, laa-
tupainotteinen elinvuosi, erikoissairaanhoito
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Summary in Swedish
Räsänen Pirjo. Routine Measurement of Health-Related Quality of Life in 
Assessing Cost-effectiveness in Secondary Health Care [Rutinbaserad mätning 
av hälsorelaterad livskvalitet vid utvärdering av kostnadseffektivitet inom den 
specialiserade sjukvården]. STAKES, Research Report 163. Helsinki, Finland 2007. 
ISBN 978-951-33-1981-6
Systematiskt insamlad information om behandlingseffekt och kostnadseffekti-
vitet är av central betydelse vid organiseringen av den specialiserade sjukvården 
i framtiden. De begränsade resurserna och den snabba utvecklingen inom olika 
hälsoteknologier förutsätter en utvärdering och prioritering av insatserna. Beslu-
ten skall vara transparenta och basera sig på undersökta fakta men framför allt på 
hur patienterna själva upplever sig ha nytta av insatserna inom den specialiserade 
sjukvården.
Syftet med denna avhandling är att kartlägga de undersökningar där behan-
dlingens utfall uppskattats i kvalitetsjusterade levnadsår på så sätt att behandling-
en bedömts av patienten själv. Dessutom avser avhandlingen att undersöka hur en 
utvärdering av den specialiserade sjukvårdens kostnadseffektivitet kunde genom-
föras inom Helsingfors och Nylands sjukvårdsdistrikt. För utvärderingen av den 
specialiserade sjukvårdens kostnadseffektivitet valdes till undersökningen tre me-
dicinska specialområden, vilka till sin volym representerar stora grupper inom den 
specialiserade sjukvården och således påverkar både samhällsekonomin och folk-
hälsan.
Antalet ekonomiska utvärderingar inom hälso- och sjukvården har ökat un-
der de senaste två årtiondena. Trots detta hittade vi på basis av vår litteraturöversikt 
endast få undersökningar, där kvalitetsjusterade levnadsår, QALY (Quality-adju-
sted life years) använts som behandlingens utfallsmätare på så sätt att man med en 
tillförlitlig metod bett patienterna själva ge en bedömning av behandlingseffekten.
Behandlingseffekten mättes utifrån en bedömning av den hälsorelaterade livs-
kvaliteten hos 712 kirurgiskt behandlade patienter före behandlingen och cirka 3–
12 månader efter behandlingen. Som mätare på den hälsorelaterade livskvaliteten 
användes ett i Finland utvecklat generiskt 15D-frågeformulär, som patienten själv 
fyller i. Alla patienter behandlades enligt normal praxis inom den specialiserade 
sjukvården. Uppgifter om behandlingseffekt kombinerades med uppgifter om be-
handlingens kostnader och arrangemang i syfte att utvärdera behandlingens kost-
nadseffektivitet.
Det rutinmässiga insamlandet av uppgifter om behandlingseffekten av de pa-
tienter som kom till den specialiserade sjukvården visade sig vara relativt lätt och 
krävde exempelvis inte avlöning av extra personal till de avdelningar där undersök-
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ningen gjordes. Svarsprocenten var i genomsnitt över 70 %, vilket visar att patien-
terna gärna deltog i undersökningen och uppskattar att man visar intresse för hur 
de mår också efter att behandlingen slutförts.
Enligt undersökningsresultaten förbättras den hälsorelaterade livskvaliteten 
hos både knä- och höftprotespatienter samt hos patienter med förträngningar i 
länd- och halskotpelaren betydligt under uppföljningstiden. Vid omoperationer 
av höftleden och starroperationer sker endast en ringa förbättring av patienter-
nas livskvalitet. Kostnaderna för den specialiserade sjukvården per patient variera-
de mellan 1 640 euro (starrkirurgi) och 11 240 euro (omoperation av höftprotes). 
Kostnaderna per kvalitetsjusterade levnadsår var lägst hos patienter med förträng-
ningar i ländkotpelaren, 1 740 euro, och högst vid omoperation av höftprotes, 
52 270 euro. 
Som slutsats kan man konstatera att en systematisk och rutinmässig insamling 
av uppgifter om behandlingseffekten och en kombinering av dessa uppgifter med 
kostnadsuppgifterna kan genomföras med relativt små ansträngningar. Under-
sökningen visade att kostnaderna per kvalitetsjusterat levnadsår varierar mycket 
mellan de olika patientgrupperna, men att kostnaderna i alla andra grupper utom 
omoperation av höftprotes är mindre än 50 000 euro, vilket inom litteraturen anses 
som ett slags takpris för en kostnadseffektiv behandling. De kvalitetsjusterade lev-
nadsåren är en viktig mätare på hälso- och sjukvårdens effektivitet. Utvärderingar, 
där de kvalitetsjusterade levnadsåren baserar sig på patienternas egen bedömning 
av behandlingen i konstellationen före–efter, borde vara en viktig metod när man 
eftersträvar att uppnå en kostnadseffektiv specialiserad sjukvård.
Nyckelord: katarakt, halskotpelare, kostnadseffektivitet, kostnadsnyttoanalys, 
höftprotes, hälsorelaterad livskvalitet, knäprotes, ländkotpelare, kvalitetsjusterat 
levnadsår, specialiserad sjukvård
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1	 Introduction
All health care systems feel the strain of relentless economic scarcity. Strategies 
to tackle the emerging problems typically aim at increasing the effectiveness of 
the care delivery system, either by improving its allocative efficiency (whether to 
allocate resources to different groups of patients with different health problems) 
or its technical efficiency (resources are distributed among the same patient 
population in an attempt to maximise health gains within the budget available), 
though preferably both (Palmer & Torgerson 1999; Dowie 2001; Shiell et al. 2002; 
Cox et al. 2006). In an ideal health care system that produces maximal health 
benefits, the marginal cost-effectiveness of care is balanced, i.e., equal across all 
care programs or technologies used.
Traditionally, investments in health care have been made without detailed 
comparative information on the health gains attained. This can be considered 
irresponsible given that the allocation of scarce resources should be based on cost-
effectiveness data, thereby ensuring the best possible return on investment. To reach 
this invaluable goal both the marginal effectiveness and the marginal costs tied into 
different technologies should be known. In reality, we usually do not know either 
of them.
Allocation decisions based on clinical results alone may lead to an inappropriate 
distribution of resources regarding societal welfare. Thus, when considering various 
alternatives, one should, in addition to the expected gains, also take into account 
the lost opportunities that inevitably follow an investment decision. Resource 
allocation should, under optimal conditions, generate maximal benefits for the 
society but, especially in health care, allocation decisions are often combined with 
significant uncertainty.
In publicly funded health care systems, such as with the majority of specialised 
health care in Finland, limited resources mean that every available intervention 
cannot be provided in every situation to all who may need or want it. Choices must 
be made among effective health care interventions, and the decision to fund one 
can mean that others cannot be funded.
To estimate the allocative efficiency of care is the most important goal of all 
health care technology assessment. For this purpose, it often uses information 
derived from randomised controlled trials (RCTs). A problem with this approach, 
however, relates to the fact that the efficacy (the extent to which an intervention is 
active when studied under controlled research conditions) of any given technology 
thus measured does not nearly equate with that of its effectiveness (the extent to 
which an intervention produces an overall health benefit in routine practice) (Guide 
to Methods of Technology Appraisal, 2004). In most cases the cost-effectiveness of 
any technology may be severely reduced when the RCT study setting is replaced by 
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an everyday clinical environment. This is as a consequence of a systematic threefold 
bias, all in favour of the RCTs: 1) due to the multiple exclusion criteria common 
in RCTs, the patients lack the required similarity to the unselected clinical patients 
2) the institutions participating in most trials represent the highest quality of any 
care under study instead of average providers; and, 3) in RCTs that consider surgical 
technologies, even the purely technical skills of the surgeons are systematically well 
above the average. Since all three factors overestimate the cost-effectiveness of any 
given technology, the resultant estimate may have little to do with the everyday 
cost-effectiveness of the technology (Hay 1999). Therefore, the effectiveness of 
any care cannot be extrapolated from its demonstrated efficacy. Instead, its true 
effectiveness must be measured.
The measurement problems, however, are not limited to the efficacy–
effectiveness divide described above. Effectiveness, according to one often used 
interpretation, deals with so-called natural units of benefits gained, such as 
mortality, life-years, or days of absenteeism. According to this definition, the 
subjectively perceived quality of life does not enter the picture at all. Yet the 
everyday practice reveals that severely ill patients trade the quality of life actively 
even against the length of their own lives. Thus, without the inclusion of the health-
related quality of life (HRQoL) aspect into the outcomes of all care, the rational 
medical decision-making may be distorted. Consequently, the way forward is to 
create a data collection system to measure the HRQoL of patients prior to and after 
most or all care delivery. Although of crucial practical significance, this has thus far 
not been systematically done anywhere in the world. In addition, also information 
about the costs related to outcomes is likewise needed to be able to estimate the 
cost-effectiveness of care as well.
After understanding the significance of effectiveness and HRQoL, a choice must 
be made between different HRQoL approaches, i.e., whether to use disease-specific 
or general HRQoL measures. The former are tailored to specific diseases, while the 
latter are constructed – as the name implies – for any given condition with reduced 
health. The disease-specific measures are more sensitive when measuring the point 
estimate or any change in any given condition. However, since the measurement 
is tuned according to the clinical expression of the measured condition, there is 
no way to compare the results in two different patient groups, not even within a 
single clinical specialty (like arthropathy and back-pain patients in orthopaedics). 
To make the outcomes measurement comparable, a generic HRQoL measure is 
thus necessary instead of a disease- or condition-specific HRQoL measure. The 
measurement of HRQoL by using a generic instrument that produces a single index 
number on a 0-1 scale –which reflects the trade-off between length and quality of 
life – also offers the significant advantage that effectiveness can be expressed in 
the form of quality-adjusted life years (QALYs) gained, which combine the change 
both in the length and quality of life. In recent years the QALY has been recognised 
as the most important indicator of effectiveness of health care interventions to 
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date. For instance, the National Institute for Health and Clinical Excellence (NICE), 
which provides national guidance on treatments and care for those using the NHS 
in England and Wales, uses the QALY as its principal measure of health outcomes 
(Rawlins & Culyer 2004; Rawlins & Dillon 2005).
In secondary health care, for instance in the framework of a large referral 
hospital like the Helsinki University Central Hospital (HUCH), the information on 
allocative efficiency of care is especially crucial. In a large organisation it is difficult, 
if not impossible, without systematically and routinely collected data to judge 
which intervention to use, what works, how well it works, at what cost, for whom, 
in what circumstances, and what is effective. In Finland, the idea of measuring the 
cost-effectiveness of secondary health care by using a standard generic HRQoL 
instrument (15D) was presented in 1996 (Sintonen). Pilot projects since have 
demonstrated that such an approach is feasible (Blom-Lange 1998; Kukkonen 
2005). 
Although previous smaller studies have indicated that systematic collection 
of HRQoL data is feasible, the question about the feasibility of large-scale routine 
data collection in the everyday practice of a large hospital, i.e., not in the framework 
of a research project, still remains open. Therefore, the aim of this study was to 
test the feasibility of collecting effectiveness data using the generic 15D HRQoL 
instrument in several medical units in the HUCH, and of combining these data with 
routinely collected cost data to create a means for estimating the cost-effectiveness 
of secondary and tertiary health-care services.
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2	 Review	of	the	literature
2.1 Economic evaluation
An economic evaluation is a comparative analysis of alternative courses of action in 
terms of both their costs and consequences (Drummond et al. 2005). With economic 
evaluation it is possible to get information about whether an intervention is cost-
effective, i.e., worth providing or not (Guidelines for the Economic Evaluation 
of Health Technologies, 2006). The basic tasks of any economic evaluation are 
to identify, measure, value, and compare the costs and consequences among the 
alternatives being considered (Drummond et al. 2005).
Central to the area of health economics are the concepts of opportunity cost 
and incremental change. Relevant information is generated by economic evaluation, 
which measures the relation between the health effects and costs of various 
interventions. The basic question in economic evaluation centres on incremental 
cost-effectiveness: On the one hand, what are the health effects of an intervention 
that is costed in monetary units, and on the other, what health benefits are lost 
when the resources are not invested in the alternative intervention.
Appropriate criteria that should be used in setting priorities in a publicly 
funded health care system are as yet unfortunately far from clear. From a health 
economic perspective, one criterion that might be considered as part of the 
decision-making process when setting health care priorities is the maximisation of 
QALYs (Stirling et al. 2002).
2.1.1 Why economic evaluation in health care? 
In health care choices must be made between services, as scarce resources preclude 
the use of all available interventions. The importance of right choices becomes 
more and more evident as the population is ageing and the variety of new, usually 
expensive, interventions seems to be ever increasing.
The fundamental purpose of health care is to produce as much health as 
possible. This means that the resources available should be directed to interventions 
that are as effective as possible in relation to their costs. In order to ensure that health 
care resources are used in the most appropriate manner and to achieve maximal 
patient benefit, health care decision-makers need to adopt robust processes for 
setting priorities. For this they need economic evaluations that provide information 
that is useful, relevant, and timely (Raftery 1998; Drummond & McGuire 2001). 
Unfortunately, the choices made in health care are not always based on scientific 
evidence on the effectiveness, let alone the cost-effectiveness, of interventions. 
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Effective health care is achieved in an ethically sound way by choosing the 
most cost-effective interventions. Efficient health care makes it possible to offer 
patients the best possible care by the means of the most cost-effective interventions. 
However, the maximisation of efficiency, i.e., cost-effectiveness, must not be such an 
overriding goal that other considerations such as equity are forgotten (Drummond 
et al. 2005; Tugwell et al. 2006). Deviations from efficiency maximisation are 
desirable, indeed necessary, on the basis of commonly accepted, and preferably 
officially endorsed, equity criteria, which reflect the value climate in the society. 
2.1.2 Different types of economic evaluation
There are four main types of economic evaluation:  cost-minimisation analysis 
(CMA), cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-
benefit analysis (CBA). The difference between them relates to how the health 
effects of health care interventions are measured and valued. The purpose of the 
study and what kind of data is available are crucial when choosing the type of the 
analysis.
2.1.2.1 Cost-minimisation analysis (CMA)
The CMA is applicable if the effectiveness of the interventions being compared has 
been shown to be the same. Then only the cost difference between the interventions 
is determined. A CMA asks the question, “Which intervention is the least expensive 
given that they are equally effective?” As the clinical effectiveness of the interventions 
being compared is only rarely exactly the same, the usefulness of CMA is limited. 
It can be employed, for instance, in cases where a new treatment shortens hospital 
length of stay without otherwise affecting the cure of the patient compared to the 
alternative treatment.
2.1.2.2 Cost-effectiveness analysis (CEA)
In CEA it is necessary to identify, measure, and value both costs and health 
outcomes. Health outcomes are measured in simple, one-dimensional natural units, 
for example life years gained or disability avoided. CEA reveals the relationship 
between the resources used (costs) and the health benefits achieved (effects) for a 
health or medical intervention compared with an alternative strategy. CEA asks the 
question, “What is the comparative cost of the two interventions per outcome?” 
(Petitti 2000). A CEA can also utilise structured health or quality of life measures 
that have not been valued with regard to population preferences.
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2.1.2.3 Cost-utility analysis (CUA)
CUA is very similar to CEA, but the outcomes used for CUA differ from those of 
CEA. In fact, CUA is a form of CEA, in which the cost of the studied intervention 
is related to the change in the length and/or quality of life resulting from the 
intervention. It thus allows for HRQoL adjustments to a given set of treatment 
outcomes, while simultaneously providing a generic outcome measure for a 
comparison of costs and outcomes in different programs. The health outcome is 
usually measured as the number of QALYs gained. The results of CUAs are typically 
expressed in terms of cost per QALY gained. Despite differences in the outcomes 
employed, the terms CUA and CEA are often used as synonyms (Drummond et al. 
2005). Even if utility is an economic concept that reflects the desirability or value of 
an activity to an individual, a cost-QALY analysis would be a more illustrative term 
for this type of analysis than cost-utility analysis. 
CUA can be recommended especially for situations in which HRQoL can 
be considered an important outcome of the studied intervention. It also serves 
as an advisable way to analyse outcomes when the studied intervention affects 
both morbidity and mortality, or the intervention has a wide range of different 
outcomes and it is necessary to have a common unit that takes into account all of 
them. CUA may also help decision-makers to set priorities and to decide which 
interventions to downgrade or eliminate when facing limited financial resources 
(Drummond et al. 2005).
A CUA, however, is sometimes problematic. The different methods and 
instruments that are used for measuring preferences for health states often 
produce different scores for the same health state. Furthermore, comparing a 
chronic condition with an acute or a mild to severe condition may pose difficulties. 
Consequently, the results of a CUA – as with the results of other types of studies – 
must always be interpreted with care.
Although it is not without its critics, cost-utility analysis is recommended 
for several reasons: It captures gains from both prolongation and quality of life 
in a single measure, it incorporates the value that people place on different health 
outcomes or their preferences for particulate health states, and it provides a 
convenient means of comparing analyses of diverse interventions and conditions 
(Neumann et al. 2000).
2.1.2.4 Cost-benefit analysis (CBA)
In CBA the costs and health consequences of treatment are measured and valued 
in monetary units. Consequently, CBA relates the net monetary gain of treatment 
to its costs. CBA addresses the question, “what is the overall economic trade-off 
between the interventions?” The results of CBA may be stated either in the form 
of a ratio of costs to benefits, or as their simple sums referred to as net benefit 
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(Drummond et al. 2005). The strength of CBA is that it may be easier to understand 
than analyses employing QALYs or life-years gained (LYG). On the other hand, the 
monetary value of a health gain is in most instances difficult, if not impossible, to 
determine. Although CBA may be useful in some situations, it should generally be 
regarded as a secondary analysis.
2.2 Costs
It is usually recommended to carry out economic evaluations from a societal 
perspective, which entails identifying, measuring and costing the use of all resources 
related to the alternatives being compared,  regardless of to whom the costs accrue. 
The resource use and associated costs are classified into several categories.
Direct health care costs include the value of health care resources directly 
consumed by the interventions to be evaluated: capital goods like building site, 
buildings, facilities, equipment, energy, materials and consumables like hospital 
and other prescribed drugs, and working time of different types of personnel.  The 
value of resources used in treating any possible side effects of the intervention also 
belongs to direct health care costs. 
Direct non-health care costs include the value of resources from outside 
health care that are directly required when using the service under evaluation. Such 
resources are, for instance, social services like home help or care in social sector 
institutions, special schooling, child care and voluntary services, over-the-counter 
medicines, special clothing and diet, appliances, home adaptation, and travel costs. 
Direct non-health care costs also encompass the value of time directly required 
from the patients when they use the service, including travel and waiting time, 
time required by diagnostics and treatment, and the value of time required from 
the carers (parents, spouse, relatives etc.) at home and when accompanying the 
patient to health service facilities. The value of time required from the patients 
and carers is also referred to as time costs (Sintonen 2007). The value of healthy 
time should also be considered when assessing non-health care costs, although this 
does pose difficulties (Drummond et al. 2005). Productivity costs, earlier referred 
to as indirect costs, arise from reduced productivity due to illness affecting time at 
work or complete temporary (sick leave) or permanent loss of ability to work due 
to disability and/or premature death. The threshold at which time costs turn into 
productivity costs is vague. 
The future health care costs (or savings) that are directly attributable to the 
intervention are the increased (or decreased) costs due to a health care intervention’s 
effect on the individual’s longevity. The handling of unrelated future medical costs 
is important because they can be large enough to raise the CE ratio substantially. 
The impact is greatest when the intervention primarily extends life (Garber & 
Phelps 1997). There is some controversy over how to treat the so-called future costs 
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(Stone et al. 2000; Petitti 2000). They should include the costs, benefits and cost-
savings related to the disease being studied, but it is still under debate whether 
they should also include costs for diseases unrelated to the intervention in question 
(Gold 1996).
Which costs are included in the analysis will vary depending on the timeframe 
and perspective being considered in a study. Most guidelines suggest the use of a 
societal perspective (Drummond & Jefferson 1996; Gold et al. 1996). This means 
that also costs accrued outside health care should be included.
Stone et al. (2000) identified in a literature review the cost components that 
have been included in published CUAs. They found that in nearly all of the included 
studies  the analysts had included some direct health care costs. Direct non-health 
care costs and time costs were generally lacking, with only 17 % including them, as 
were productivity costs, which were included in only 8 % of the studies.
2.2.1 Costing in practice
The costing procedure can be divided into three phases: identification, measurement 
and valuation.
First it is important to identify the relevant use of resources involved in the 
health technologies to be compared. The choice of perspective for the analysis is 
momentous. Methods such as a review of earlier studies in the area, pilot studies, 
modelling exercises or expert advice can help to identify the relevant resource use 
(Kristensen et al. 2001).
In measuring resource use the typical units are physical units like time 
consumption of health professionals, inpatient days, medicines taken, number of 
tests and operations, number and duration of visits to a general practitioner, days of 
absence from work, etc. Potential methods and data sources for the collection and 
measurement of resource use are case record forms, cost diaries, questionnaires or 
interviews, register and data files, pilot studies, clinical databases, earlier studies or 
expert advice. It is often a good idea to combine some of the methods (Kristensen 
et al. 2001).
The value of resource use should ideally be the opportunity cost. Opportunity 
costs, however, are difficult to measure in practice. Market prices are only one 
way of valuing the costs of resource use; the others are charges, average costs 
and marginal costs. When real costs are measured as part of a micro-costing or a 
patient-specific costing approach, either marginal or average costs might be used 
(Larsen et al. 2003). Marginal costs are the costs that are expected to vary according 
to the number of patients treated, and express the cost of using one extra unit 
of resources. Average costs also include the resource use that does not vary with 
the number of patients treated, like for instance capital costs and other fixed costs 
(Larsen et al. 2003).
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Stone et al. (2000) evaluated sources of cost valuations in cost-utility analyses 
and found that the most frequently used source was published estimates, followed 
by charges, institutional-based accounting and expert opinion.
2.3 Decision rules of cost-utility analysis
To differentiate which health technology is cost-effective, both the total costs and 
the effectiveness of at least two interventions have to be compared. The comparison 
may lead to nine different situations described in the decision-matrix below (Table 
1).





Less effective Same effectiveness More effective




4.Adopt the new 
technology
the new dominates 
the old (weak 
dominance)
.Adopt the new 
technology
the new dominates 
the old (strong 
dominance)
Same costs 2.Keep the old 
technology




.Adopt the new 
technology
the new dominates 
the old (weak 
dominance)
More costly 3.Keep the old 
technology
the old dominates 
the new (strong 
dominance)
.Keep the old 
technology
the old dominates 






In situations described in cells 1 and 9 marginal or incremental analysis is needed 
to decide which technology is preferable. For that purpose the incremental cost-
effectiveness ratio (ICER) has to be calculated. It is a ratio of the difference in costs 
of interventions to the difference in outcomes. The new intervention is considered 
cost-effective if the society is willing to pay for the additional benefits (cell 9) or if 
the society considers that the cost savings compensate for the lower effectiveness 
(cell 1).
When calculating the ICER in the situation depicted in cell 9, one inevitably 
faces the question whether there is a willingness-to-pay threshold, which indicates 
what might be the maximum incremental cost that the society is willing to pay for 
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a QALY gained. Some countries use a formal threshold. Rawlins and Culyer (2004) 
suggest that NICE in the UK bases decisions primarily on an ICER below £20 000/
QALY gained. However, Parkin and Devlin (2004) found that NICE’s threshold 
is probably between £20 000–30 000/QALY gained. To determine a universally 
accepted, official threshold value for the willingness to pay for a QALY is an 
impossible task as resources available for health care vary from country to country, 
and also other factors like uncertainty and burden of disease must be taken into 
consideration (Devlin & Parkin 2004).
2.4 Quality-adjusted life year as an outcome  
 measure
CUA has increasingly been recognised as the preferred method to assess the cost-
effectiveness of care (Zentner et al. 2005). Following on from this preference, health 
outcomes can be measured in terms of QALYs gained, which is an outcome measure 
that takes into account and combines within a single measure both changes in the 
quantity and/or the quality of life produced by a health care intervention. It is 
an arithmetic product of the life expectancy and the quality of the remaining life 
years. QALYs are often used to describe health outcomes of interventions, based 
on data collected at baseline and at one or more points of follow-up (Manca et al. 
2004). As QALYs can be used to express the sum of individual utility gains from 
medical interventions, they are, as such, potentially a useful measure in deciding 
how to allocate resources (Nord 1999).
The calculation of QALYs can be presented by the simple equation: QALYs = 
Ui  * t (where Ui represents the utility score for health state i and t represents the 
amount of time spent in health state i).  The example in Figure 1 below shows how 
the length of life (horizontal axis) and the health outcome in terms of HRQoL 
(vertical axis; on a 0–1 scale) can be combined. The values on a 0–1 scale are 
referred to in the literature as utilities, preference weights, quality weights or values 
of health states. In the example the duration of health state1 is k1 and its utility 
v1.  State 1 is followed by state 2, the duration of which is k2 and the utility v2. 
Finally, state 3 with a utility of v3 lasts until death. Thus the sum k1v1+k2v2+k3v3 
(white area under the curve) depicts the number of QALYs without treatment 
(QALY0). With treatment HRQoL is improved to a higher level and then HRQoL 
deteriorates more slowly and the length of life is longer. The area under the upper 
curve represents the number of QALYs with treatment (k4v4+k5v5+k6v6+k7v7
=QALYw) and the difference between the two areas (grey area) the incremental 
number of QALys gained by treatment (QALYw-QALY0). This area is used as the 
indicator of effectiveness of treatment in CUA (Drummond et al. 2005; Sintonen 
2007).
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FIgURE 1. Description of the effectiveness of an intervention by quality-adjusted life years 
gained (Sintonen 1994). Reprinted with permission of PharmacoEconomics.
Although the QALY is currently regarded by most researchers as one of the most 
important indicators of effectiveness of health care, there has also been some 
criticism towards the use of QALYs, particularly when used as a guide for resource 
allocation or clinical decision-making. HRQoL is a subjective measure that can vary 
widely among patients, populations, and practitioners. Furthermore, it matters 
whose HRQoL weights are used for calculating QALYs. Some prefer that the HRQoL 
weights should be based on patient preferences, others that they should be based 
on the preferences of the general public. Measuring QALYs requires researchers 
also to make many ethical assumptions regarding what defines HRQoL, equity 
and efficiency, and individual and societal preferences. According to Bozic et al. 
(2003), several authors have also noted that QALYs have flaws related to variability 
in individual appreciation of life values. 
Furthermore, the QALY has been criticised for favouring younger patients and 
for not taking the severity of the disease into account. The QALY approach also 
assumes that the relative weights for health states are independent of the duration 
of the health states. By using QALYs, it is assumed that a small gain to many people 
is equally as desirable as a large gain to a few, so long as the QALY totals are the 
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equal to a gain of 25 QALYs each to four individuals). (Guidelines for economic 
evaluation of pharmaceuticals, 1997)
The healthy years equivalent (HYE), the disability-adjusted life years (DALY), 
and the saved-young-life –equivalent are alternatives to the QALY (Drummond 
et al. 2005). The DALY, however, has been criticized for several of its properties 
(Arnesen & Nord 1999) and has not gained as widespread acceptance as the QALY. 
The same applies to HYE and SAVE: In a systematic literature review evaluating 
methods used in cost-utility studies between 1981–2000, Greenberg & Pliskin 
(2002) were able to identify only one study that used cost per HYE and none that 
used cost per SAVE. 
To be able to express the effectiveness of treatment in terms of QALYs we need 
HRQoL measurements that describe the various dimensions of health and their 
preference weights elicited from patients or the general public.
2.5 Measurement of health-related quality of  
 life
Quality of life (QoL) is a broad concept that includes many aspects of life in addition 
to health; for example wealth, freedom, the political system, and the cleanliness of 
the environment all contribute to the overall QoL. HRQoL refers to those aspects of 
QoL that are related to health (Guidelines for the Economic Evaluation of Health 
Technologies, 2006). Consequently, HRQoL is a more concise concept than quality 
of life per se and considers mainly aspects of life that can be affected by health care 
or health policies.
HRQoL reflects the physical, psychological and emotional dimensions of 
health (Gold et al. 1996). It can be used to describe the effects of an illness on 
the quality of life and the effect of clinical interventions on health and general 
well-being (Kauppinen 1999). In addition to the disease and its treatment, HRQoL 
is affected by the general condition of the individual in question, other health 
problems and sickness experiences he may have, and his phase of life, as well as his 
activities and goals.
There are numerous ways to assess HRQoL: disease-specific, generic, or 
preference-based (utility) measurements tools. The different dimensions of health 
can be described with various generic or disease-specific instruments. The generic 
instruments allow the comparison of a variety of patient groups, whereas the 
disease-specific instruments only give information on the effect of a certain disease 
on health and are thus not suited for a comparison of treatment results across 
different diseases.
As already stated above, the terms utility, value and preference are often 
used as synonyms, although strictly speaking there are differences between them. 
2
2   REVIEW OF THE LITERATURE
STAKES 2007
Drummond (2005) defines preference as an umbrella term that describes the 
overall concept; utilities and values are different types of preferences. Preference 
weights differ from measures of functional health status, because they measure 
how patients or population feel about their health and ability to function rather 
than how they actually function (Tosteson et al. 2000). Preference-based measures 
provide a summary score that numerically reflects the HRQoL, and are the only 
approaches that are suitable for use in a CUA.
The choice of utility instrument can be expected to have a large impact on 
the results of cost-utility studies (Stavem 1999). For example, Brazier et al. (2004) 
found in their study that when comparing seven patient groups, there are differences 
between the results obtained with different HRQoL measures (EQ-5D vs. SF-6D). 
Reasons for this are the differences in the health state descriptive system and the 
methods used to value the health states defined by the descriptive system. So far, 
however, no single measure of HRQoL has been accepted as the gold standard.
There are two major methodological problems in constructing an HRQoL 
measure that produces a single index score. One is the creation of a standardised 
health state descriptive system, i.e., the choice of the dimensions (attributes) in 
which health is to be measured and the division of each dimension into discrete 
levels, by which more or less of the attribute can be identified. Another is the 
valuation of the different combinations (profiles) of the levels, one from each 
dimension, i.e., of the health states thus defined. 
2.5.1 Disease-specific instruments
Any generic instrument that is simple enough to be applied across different 
interventions may lack sensitivity to important differences in health status that 
are essential for particular diseases. For that reason disease-specific measurements 
have an important role in assessing the effectiveness of treatment (Petitti 2000). 
Disease-specific instruments focus on the issues most relevant to patients’ health 
concerns, having the detail to detect small, though clinically important changes in 
health status. They are thus not suited for a comparison of treatment results across 
various diseases (Drummond et al. 2005). Their main purpose is to assist in clinical 
decision–making, though they are also usually sensitive in measuring the results of 
specific treatments. Good examples of disease-specific instruments are for instance 
the Knee Society Score (KSS), which evaluates pain and mobility in patients with 
knee problems (The Knee Society 2006), and the Harris Hip Score (HHS), which 
has been designed for the assessment of symptoms of hip disorders (Harris 1969).
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2.5.2 Generic instruments
The generic instruments can be used for diverse patient groups independent of 
the underlying disease or disability. Generic instruments can be methodologically 
classified into profile and single index score measures. The former describe the 
health state from the stand point of various physical and emotional dimensions 
such as vitality, role limitations caused by emotional difficulties, bodily pain, 
general health, social function, etc. as in the widely used SF-36 instrument (Ware 
et al. 1995). The latter instrument produces a single index score on a 0–1 scale 
(although some instruments produce also negative scores), which is a necessary 
requirement for the calculation of QALYs used for a commensurate appraisal 
of the cost-effectiveness of various health care interventions. When choosing an 
HRQoL instrument, special attention needs to be paid to its empirical, theoretical, 
and technical characteristics, such as validity, reliability, sensitivity, usability, and 
interpretability (Gerard 1992; Fitzpatrick et al. 1998; Drummond et al. 2005). 
Generic, single index score instruments include for instance the EQ-5D (EuroQol), 
SF-6D (derived from RAND-36/SF-36), HUI 3 (Health Utilities Index Mark III), the 
AQoL (Assessment of Quality of Life) and the 15D (Gerard et al.1999; Drummond 
et al. 2005). 
HRQoL instruments differ regarding the methods they use for measuring 
preferences and from whom the preferences are obtained. The same patient group 
can get a quite different HRQoL score on the scale of 0 to 1 depending on the 
method used. So far, there is no consensus which HRQoL instrument is the most 
effective to use. 
2.5.3 15D
The development of the 15D questionnaire started in the late 1970s. The idea 
of the instrument was to combine the advantages of a profile and a preference-
based measure. The first version in the early 1980s was a 12-dimensional system 
(Sintonen 1981). The first version of the 15-dimensional health state descriptive 
system emerged in 1986 (Sintonen & Pekurinen 1989 and 1993).
The present version of the 15D originating in 1992 consists of 15 dimensions 
(moving, seeing, hearing, breathing, sleeping, eating, speech, eliminating, usual 
activities, mental function, discomfort and symptoms, depression, distress, vitality 
and sexual activity) each with five levels, leading to 515 possible combinations of 
answers describing different health states. For each dimension, the respondent 
must choose one of the five levels that best describes his/her state of health at the 
moment (the best level = 1; the worst level = 5).
The valuation system of the 15D is based on an application of the multi-
attribute utility theory. A set of utility or preference weights, elicited from 
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representative samples of the general public through a 3-stage valuation procedure, 
is used in an additive aggregation formula to generate the utility score, i.e., the 
15D score (single index number) over all the dimensions. The maximum score is 1 
(no problems on any dimension), and minimum score 0 (being dead). The scores 
are suitable for QALY calculations. A change in the score of ≥ 0.03 is considered 
clinically significant or important (Sintonen 1995).
In most of the important properties the 15D compares favourably with other 
instruments of that kind (Stavem 1999; Hawthorne et al. 2001; Sintonen 2001) and 
the instrument has been widely used in patients with different diseases in different 
countries. The questionnaire is available in more than 20 languages. Based on the 
15D, a 16D version has also been developed for adolescents aged 12–15 years and 
17D for children aged 8–11 (Apajasalo et al. 1996 a & b; www.15D-instrument.
net). 
2.6 Prior experiences of routinely evaluating  
 cost-effectiveness in secondary health care 
In Finland, the idea of measuring the cost-effectiveness of secondary health care 
by using a standard generic HRQoL instrument (15D) was presented in 1996 
(Sintonen 1996).  Pilot projects since have demonstrated that it is feasible (Blom-
Lange & Sintonen 1998). 
Blom-Lange (1998) and Blom-Lange & Sintonen (1998 & 2000) evaluated 
the feasibility of measuring the effectiveness of routine hospital treatment in the 
Päijät-Häme Central Hospital, Finland. The main aim of the research was to define 
the most appropriate point of time to assess HRQoL. A total of 645 patients in 
eleven diagnostic groups filled in the 15D questionnaire at five different time-
points: when placed on the waiting list, at admission to the hospital, at discharge 
from the hospital, approximately three to four months after discharge and one to 
two years thereafter. The results of the studies indicated that it is possible to use the 
15D instrument to assess the effectiveness of hospital treatment. In all diagnostic 
groups the average 15D scores were lower at the final measurement than three or 
four months after the intervention. In addition, the research showed that patients’ 
health status did not deteriorate while on the waiting list.
Kukkonen (2005) studied 828 patients in the North-Karelia Hospital District 
in Finland by administering the 15D HRQoL instrument to patients before and up 
to four months after treatment in specialised health care. The HRQoL instrument 
proved to be comprehensive enough to be used in a mixed patient population. It 
was also shown to provide valuable input for Bayesian mathematical modelling. It 
was concluded that in the area of the North Karelian hospital district in Finland, 
specialised health care can mostly be considered cost-effective.
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A similar approach to the measurement of effectiveness has been used in 
Canada, where outcomes of elective surgery in a large group of surgical patients 
were successfully evaluated using the SF-36 (Wright et al. 2002). However, in the 
study of Wright et al. cost data were not used and, consequently, cost-effectiveness 
not reported.
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3	 Aims	of	the	present	study
The main aim of the present research was to explore the feasibility of the large-scale 
routine collection of effectiveness data using the generic 15D HRQoL instrument 
in the Hospital District of Helsinki and Uusimaa.
1. The first step of the study was to identify, in a systematic literature review, the 
cost-effectiveness studies that used QALY based on actual measurements of 
patients’ health-related quality of life as an outcome measure (Study I).
2. Secondly, building on previous experiences, we wanted to establish a system 
for the large-scale collection of effectiveness data and to test the feasibility of 
such an approach in the context of a large university hospital (Study II).
3. The third aim was to combine HRQoL data with the available cost data to 
create a means for estimating the cost-effectiveness of secondary and tertiary 
health care services routinely (Study II).
4. The fourth goal was to report and compare the cost-utility of three different 
important surgical interventions routinely performed in the Hospital District 
of Helsinki and Uusimaa (spinal surgery, cataract surgery and hip and knee 
replacement surgery) (Studies III, IV, and V).
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4	 Materials	and	methods
This thesis is based on three types of studies. Article I is a systematic literature 
review of studies that have used QALY as an outcome measure. Article II assess 
the feasibility of the routine collection of HRQoL data in secondary health care. 
In addition article II explores methods of combining these effectiveness data with 
the diagnostic and financial indicators of care routinely collected in the HUCH. 
Articles III-V report on economic evaluations for three routinely offered surgical 
interventions that constitute a significant part of the activities in the medical 
specialties of neurosurgery, ophthalmology and orthopaedics.
4.1 Systematic review of the literature
A systematic review of the literature is a research article that identifies relevant studies, 
appraises their quality and summarises their results using scientific methodology 
(Khan et al. 2003). The systematic review addresses questions formulated through 
an analysis of the evidence. It has explicit methods for searching of the literature, 
as well as having critical inclusion and exclusion criteria. The aim is to ensure a 
review that is comprehensive and unbiased and which can be used with confidence 
for decision-making in the research and delivery of health care. 
4.1.1 Search strategy for the review
Systematic searches of the literature were made, without any language restrictions, 
using the Medline (1966–June 2004), Embase (1966–June 2004), CINAHL (1982– 
June 2004), and Science Citation Index (1982–June 2004) databases and the 
Cochrane library (Issue 2, 2004) and the search strategies described in detail in 
Appendix A of the article. In addition some articles were identified by scanning 
reference lists of included articles, running a Medline search using the name of 
the principal author of each included article as the search term, and consulting 
experts in the field of economic evaluation. Finally, we also compared the results 
of our search with the listing of cost-effectiveness ratios published in the Cost 
Effectiveness Analysis Registry (http://www.tufts-nemc.org/cearegistry/). 
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4.1.2 Screening of articles
Initial screening of identified articles was based on abstracts read independently 
by two of the authors; full-text articles were again evaluated by two authors, who 
made the final decision on which articles should be included.
4.1.3 Inclusion criteria
The articles deemed acceptable for inclusion had compared in a scientifically valid 
manner the HRQoL of patients in a before–after setting and where patients had 
assessed their HRQoL with a generic HRQoL instrument recognised to produce 
a valid single index score for the calculation of QALYs (15D, EQ-5D, SF-6D, HUI, 
AQoL, QWB, Rosser-Kind), or in which the HRQoL had otherwise been assessed 
by a direct valuation method (Time Trade-Off (TTO), Standard Gamble (SG), 
Visual Analogue Scale (VAS), or Rating Scale (RS)). 
4.1.4 Evaluating the quality of the articles
The quality of the included articles was considered with regard to the study design 
used and study performance as reported by Hailey et al. (2004 a & b). For study 
design, scores were assigned to five classifications. Large randomised controlled 
trials (RCTs), defined as those with at least 50 subjects in each arm, were given 
a score of 5. Small RCTs had a score of 3, prospective non-randomised studies 2, 
retrospective comparative studies 1, and non-controlled series 0.
Study performance was established by looking at 5 aspects: patient selection, 
description/specification of the intervention, specification and analysis of study, 
patient disposal, and outcomes reported. When reviewing a study, each of these 
five aspects was given a score of 0, 1 or 2. A score of 0 was given if the relevant 
information was missing or given in only minimal detail; a score of 1 indicated 
that reasonable detail was provided, but there were some important limitations; 
and a score of 2 was given if the information provided was satisfactory, with no 
significant limitations. Each study therefore had a possible maximum score of 10 
for performance.
4.1.5 Reporting
The included articles were summarised in a table with regard to country of origin, 
intervention, clinical specialty, aim of the study, subjects, methods, perspective of 
the analysis, HRQoL instrument used, costs, results, limitations and cost/QALY.
3 STAKES 2007
Routine Measurement of Health-Related Quality of Life in Assessing 
Cost-Effectiveness in Secondary Health Care
4.2 Feasibility study
Both the feasibility study and the studies forming the bases of articles III-V were 
carried out in secondary health care. Secondary health care includes treatments 
that are provided both on an outpatient and inpatient basis in hospitals. For the 
organisation of specialised health care, Finland is divided into 20 hospital districts. 
Five of them are university hospital districts. All of them are owned by federations 
of municipalities, i.e., hospital districts (Järvelin 2002). The Hospital District of 
Helsinki and Uusimaa (HUS) is the largest hospital district in Finland. HUCH is 
part of HUS and it is a large referral hospital that provides secondary and tertiary 
health-care services for a population of approximately 1.4 million (www.hus.
fi). The Hospital District of Helsinki and Uusimaa has 32 hospitals throughout 
the province of Uusimaa. Specialised medical care in Finland refers to that part 
of health care that that is run by specialists and which covers, in addition to 
diagnostics and treatment, some preventive and rehabilitative services. Access to 
specialised care usually requires a referral from a primary care physician except 
in emergency situations. All of the major medical specialties are represented at 
HUS: surgery, medicine, anaesthesiology, physiatrics, obstetrics and gynaecology, 
illnesses of children and adolescents, neurology, neurosurgery, ophthalmology, 
otorhinolaryngology, imaging, laboratory specialties, psychiatry, oncology, 
dermatology and allergology, and venereal diseases. 
Data collection began in March 2002 and has so far covered over 11 000 
patients receiving treatment according to normal hospital routines in over 30 
distinct medical entities. HRQoL was measured before and after treatment by the 
15D HRQoL questionnaire. Some disease-specific measures were also used for 
some medical entities.
Direct costs of secondary health care were obtained from the Ecomed® 
patient administration system (Datawell Ltd., Espoo, Finland) used in the HUCH. 
This system includes, in addition to cost data, data on patient variables such as 
diagnoses and interventions performed, and organisation of services such as 
waiting times and urgency of treatment. To evaluate the cost-effectiveness of 
treatments, the HRQoL data are combined with these data. The summary costs 
used for the analysis covered all relevant specialty-related costs including pre- and 
postoperative outpatient visits to the hospital. To ensure this, collection of cost data 
covered a period starting three months prior to the date on which the first HRQoL 
questionnaire was completed and ending at the date the repeat questionnaire was 
completed. For each treated patient, all available information on treatment in the 
database (for instance diagnosis, intervention, costs, waiting time) were combined 
for the above-mentioned time period with the HRQoL information.
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4.3 Patients for the cost-utility analyses (III,  
 IV and V)
4.3.1 Neurosurgery (III)
In addition to life-saving interventions (like for instance surgery of intracranial 
aneurysms) neurosurgeons often perform operations aimed mainly at relief of pain. 
These include operations for benign back disorders which, although they usually 
have a good long-term prognosis, may severely reduce a patient’s HRQoL (Daffner et 
al. 2003) and be associated with prolonged suffering and inability to work.
Cervical disc disease accompanied by spondylosis may cause neurological 
dysfunction via ventral compression of the spinal cord or nerve roots, neck pain, 
or a combination of symptoms (Angevine et al. 2005). Many studies have shown 
that a variety of cervical interventions lead to positive postoperative results judged 
by both physician-assessed (Bertalanffy et al. 1988; Gaetani et al. 1995; Bucciero 
et al. 1998; Sampath et al. 2000; Goldberg et al. 2002) outcomes as well as patient-
reported outcomes.
Cervical stenosis is a degenerative disease where the spinal canal and neural 
foramina narrow and compress the spinal cord and nerve roots. Low back (lumbar 
spine), mid back (thoracic spine) and neck (cervical spine) pain syndromes 
adversely affect the function or well being of an individual and are attributable 
to many non-malignant aetiologies. Lumbar radiculopathy is a common problem 
that results when nerve roots are compressed or irritated. Low back pain resulting 
from degenerative disease of the lumbosacral spine is a major cause of morbidity, 
disability and lost productivity. Treatment for symptomatic lumbar stenosis is 
usually surgical decompression.
In the HUCH neurosurgeons perform around 3000 operations annually. Of 
them approximately 700 (23 %) represent demanding back operations. The majority 
of the operations concern the cervical spine (over 400 operations annually), the 
rest complicated disorders of the thoracic or lumbar spine (http://www.hus.fi).
Between April 2002 and April 2003 546 patients undergoing spinal operations 
at the Department of Neurosurgery of the HUCH were asked to complete the 15D-
questionnaire. Of them 70% returned the baseline questionnaire. The follow-up 
questionnaire was administered approximately three months after the operation 
and was returned by 311 patients (82 % of those that responded to the first survey). 
However, 12 patients were excluded from the final analysis because they had filled 
in the HRQoL survey after the operation and five patients because of incomplete 
data.
Altogether 270 patients were available for the final analysis. As the total 
number of spinal operations in the department of Neurosurgery in 2002 was 687, 
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our sample represents approximately 40 % of the total number of patients operated 
on for spinal disorders per year.
4.3.2 Ophthalmology (IV)
A cataract is opacity of the lens of the eye that disturbs the passage of light to the 
retina, thus impairing vision. Vision problems like cataract are conditions that may 
not directly affect the length of life but may negatively affect its quality.
According to the Finnish Current Care guideline a cataract operation is 
indicated if it impairs a patient’s quality of life and ability to manage with work 
or daily activities and the patient wishes to have surgery after having received 
adequate information on the expected benefits and risk factors of surgery. Special 
indications for cataract surgery include the treatment and monitoring of diseases 
of the posterior eye (for instance diabetic retinopathy, retinal diseases), open angle 
glaucoma, phacodonesis and the repair of anisometropia. Cataract surgery is also 
indicated if a hypermature cataract causes an inflammation in the eye (phacolysis, 
phacoanaphylaxis), constriction of the iridocorneal angle or a refractory open-
angle glaucoma (Käypä hoito -suositus [Current Care Guideline] www.kaypahoito.
fi).
Cataract surgery is the most common surgical operation in ophthalmology. 
The rate of cataract surgery in Finland has been increasing every year, though 
since the recent introduction of national guidelines for treatment indications for 
cataract, the number of operations has shown a small decline (Punnonen 2007). 
In 2002, over 40 000 cataract operations were performed in Finland (Käypä hoito 
-suositus [Current Care Guideline] www.kaypahoito.fi). In the future the demand 
for cataract surgery is expected to increase as the population ages.
In the field of ophthalmology 386 patients scheduled for routine cataract 
operation in the Helsinki University Eye Hospital between August 2002 and June 
2003 were invited to participate and complete the 15D questionnaire. A follow-up 
survey was mailed approximately six months after the operation to all patients who 
returned the baseline questionnaire. The follow-up questionnaire was returned 
by 73 % of those that responded to the first survey. Seven cases were removed 
from the final analysis because of incomplete data, 32 patients because they had 
filled in the baseline questionnaire after the operation, six patients because they 
had filled in the follow-up questionnaire less than 60 days after the operation on 
the second eye, seven patients because the eventual intervention performed was 
more extensive than a plain cataract operation, and 11 patients because their final 
principal diagnosis was not cataract. 219 patients were available for final analysis. 
In 2002, the total number of cataract operations in the HUCH was 4862, of which 
1164 were performed in the ward used for our study. Our sample thus represents 
3
4   MATERIALS AND METHODS
STAKES 2007
approximately 19 % of the cataract operations performed per year in the ward 
taking part in the study.
4.3.3 Orthopaedic surgery (V)
In the field of orthopaedics hip and knee replacement comprise a major area. 
The number of hip and knee operations has been constantly increasing (Lehto et 
al. 2005) and, for instance in 2002, 5760 primary total hip arthroplasties (THA) 
and 6121 primary total knee arthroplasties were performed in Finland (Mikkola 
et al. 2005). This corresponds to 112 hip and 118 knee operations per 100 000 
inhabitants.
Total hip replacement is an accepted and widely used procedure for advanced 
osteoarthritis of the hip. It relieves symptoms of pain and helps to restore the loss 
of function that follows hip arthritis. The most common indications for total hip 
replacement are osteoarthritis, fracture, rheumatoid arthritis and aseptic bone 
necrosis (Towheed & Hochberg 1996). It is primarily done to improve HRQoL 
rather than to extend life (Chang et al. 1996). The favourable effect of hip and 
knee replacement surgery on HRQoL is well established (Rissanen et al. 1995; 
Dawson et al. 1996, Norman-Taylor et al. 1996; Rissanen et al. 1996, Towheed & 
Hochberg 1996). In addition, several studies have suggested that total hip and knee 
arthroplasty are both relatively cost-effective compared to many other health care 
interventions (Laupacis et al. 1994; James et al. 1996; Rissanen et al. 1997; Garellick 
et al. 1998; O’Shea et al. 2002; Segal et al. 2004). The estimates of cost-effectiveness, 
however, have usually been based on results of individual studies comparing only 
two or a few interventions at a time. The widely held view of the favourable cost-
utility ratio of THA or TKA, compared to many other interventions, is still subject 
to some uncertainty.
In the Department of Orthopaedics at HUCH, data collection began in March 
2002 and ended in August 2002. A total of 358 consecutive patients admitted for 
scheduled hospital treatment were invited to participate. Approximately six and 12 
months after the operation, a follow-up questionnaire was mailed to all patients 
who had returned the first questionnaire. After data collection had commenced, and 
after excluding patients whose intervention was not for hip or knee replacement or 
who had returned only one of the two postoperative questionnaires, 223 patients 
were available for analysis. In 2002, the total number of hip and knee replacement 
operations matching our criteria in the HUCH was 1089 (46 patients underwent 
two operations). Our sample thus represents approximately 33% of the hip and 
knee replacements performed in the HUCH per year.
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4.4 Effectiveness of the interventions
The effectiveness of the interventions in terms of change in HRQoL score was 
measures by the 15D. For spinal surgery patients, the baseline 15D HRQoL 
questionnaires were mailed together with the invitation to attend the hospital. The 
cataract and orthopaedic patients were given the questionnaire by the nurses during 
the pre-operative visit to the hospital. The follow-up questionnaire was mailed to 
all patients having returned the baseline questionnaire three to 12 months after the 
operation, depending on the medical specialty studied. The timing of the repeat 
questionnaire was adjusted so that the full benefits of the operation were expected 
to have materialised at the time of the reassessment of HRQoL. All recruited 
patients received treatment according to normal hospital routines.
In addition to HRQoL, outcomes in the orthopaedic patients were measured 
by two commonly used disease-specific measures, the Harris Hip Score (HHS) 
(Harris 1969; Söderman & Malchau 2001) and the Knee Society Score (KSS) 
(Insall et al. 1989; The Knee Society 2006), at baseline and at 12 months after the 
operation.
In the cataract patient group the HRQoL in terms of the 15D profile and 
score at baseline and at follow-up was compared to that of the general population 
standardised according to the age and gender distribution of each separate patient 
group. The HRQoL data of the general population measured by the 15D came 
from the Health 2000 Health Examination Survey (Aromaa & Koskinen 2004).
4.5 Costs
The perspective taken for the analysis was that of the provider of secondary 
health care. Direct hospital costs (actual costs of production of the service from 
the hospital accounting records) relating to the observation period were obtained 
from the Ecomed® clinical patient administration system (Datawell Ltd., Finland), 
where all costs of treatment of individual patients in the hospital are routinely 
stored. Productivity costs for example due to possible periods of disability were 
not included. Cost-utility was calculated as the relation of QALYs gained to costs 
of providing surgery. QALYs for CUA were calculated using the obtained utility 
data and the expected remaining life years of the patients (Statistical Yearbook of 
Finland 2003).
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4.6 Statistics
Data were analysed using the statistical software SPSS for Windows, version 
11.0 (SPSS Inc., Chicago, IL, USA). In study IV, the R environment for statistical 
computing and graphics was also used (Ihaka & Gentleman 1996).
The results are given as mean ±SD or as mean and 95 % confidence interval 
(CI) or as median. The statistical significance of differences between pre- and 
post treatment level values of the 15D dimensions and 15D scores was tested 
using the Student paired-sample t-test. An independent samples t-test was used to 
compare the level values and 15D scores with age- and gender-standardised general 
population. A p-value of < 0.05 was considered statistically significant.
The change in 15D score was defined as the difference between the end-of-
study score and the baseline score. In cases where there were three or fewer missing 
answers on the dimensions of the 15D, the missing responses on any dimension 
of the 15D were predicted by regression models with the responses on the other 
dimensions, age and gender, as explanatory variables.
One-way sensitivity analyses were performed by varying the discount rate 
between 1–5 %, using the median values of QALY gain and costs, and using the 
upper and lower values of the 95 % CI for the mean differences in treatment 
effectiveness (HRQoL change) and costs. Cost-utility analyses were based on cost 
per QALY gained using the 15D as the basis for calculating QALYs.
In study III, to evaluate whether the HRQoL change differed between 
patients whose surgery was performed within 60 days of the preoperative visit and 
those whose surgery was delayed until after 60 days, an analysis of variance was 
performed.
In study IV the relationship between the level value of the 15D dimension of 
seeing and visual acuity in the eye to be operated on and the non-surgical eye was 
assessed by Spearman correlation. Visual acuity data obtained by the Snellen chart 
were converted to Logarithm of Minimal Angle of Resolution (LogMAR) units 
for statistical analysis using the Visual Acuity Conversion Chart (Visual Acuity 
Conversion Chart, 2005). To assess the degree of uncertainty 10000 re-samples from 
the original stochastic cost-utility data set were simulated using a bootstrapping 
technique. Bootstrap results are presented as cost-effectiveness planes and cost-
effectiveness acceptability curves. The cost-effectiveness acceptability curve is a 
method for summarising the uncertainty in estimates of cost-effectiveness.
In study V the χ2-test was used to compare percentage distributions between 
the groups.
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4.7 Ethical Considerations
All patients received the previously scheduled routine treatment and other than 
being asked to fill in the 15D questionnaire and to give a written informed consent, 
they were not approached in any other way. To avoid possible unnecessary distress to 
the relatives of the patients, whether the patients were still alive was ascertained from 
the Finnish Population Register Centre prior to mailing the repeat questionnaires. 
The Ethical Committee of the Helsinki and Uusimaa Hospital District approved 
the study protocol (registration number 26/E6/02). The trial has been registered 
in the Helsinki and Uusimaa Hospital District Clinical Trials Register (www.hus.fi) 
with the unique trial number 75370.
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5	 Results
5.1 Systematic review of the literature
The literature search identified 4 878 publications (Figure 2). However, 996 were 
reviews, letters, or editorials and, given that were looking for original studies, were 
not included for further review. Furthermore, the 996 articles were excluded if 
they included publications dealing with prevention or screening, topics which had 
been decided to be excluded from the review. Thus we were left with 3882 articles 
altogether that potentially reported QALYs as outcome measures. After screening 
of abstracts, 624 full-text articles were selected for closer inspection. Of them 72 
(representing 70 separate studies) were deemed to fulfil the selection criteria and 
were included in the review. In 80 cases (13 % of the 624 full-text articles) the initial 
evaluation by the two independent reviewers differed regarding whether the article 
was based on clearly identifiable HRQoL data obtained with a valid instrument or 
not. In those cases the article was also evaluated by a third evaluator and the final 
decision was made in a consensus meeting. Of those 80 articles, 18 were finally 
deemed to merit inclusion in the review.
FIgURE 2. Flowchart showing the selection of articles 
4 878 articles
996 articles removed
3 882 abstracts read
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The most frequently used HRQoL instrument in the identified studies was EQ-5D, 
which had been used in 47 % of studies, followed by HUI (8.8 %), the Rosser-Kind 
Index (6.3 %), QWB (6.3 %), SF-6D (5.0 %), and 15D (2.5 %). The rest (24 %) used 
a direct valuation method (TTO, SG, VAS or RS). The most often studied medical 
specialties were orthopaedics (15.5 %) followed by pulmonary diseases (13 %), 
and cardiology (9 %). The most commonly studied interventions were treatment 
of coronary heart disease, total hip arthroplasty, and cochlear implant, with four 
studies concerned with each of them. Ninety percent of the studies came from four 
countries: the United Kingdom, the United States, Canada and the Netherlands. 
Approximately half of the articles were randomised trials with high-quality 
methodologies. An economic analysis was included in 86 % of studies and four of 
them were based on economic modelling. The mean number of QALYs gained by 
various interventions varied widely as did the costs per QALY gained. Nearly half 
of the studies concluded that the studied intervention was cost-effective.
5.2 Feasibility
During the study period considered here (from March 2002 to March 2004) 4900 
patients returned the first questionnaire and 2680 the follow-up questionnaire. The 
average response rate to the first questionnaire was over 70 percent, but there was 
some variation between different clinical specialties. To date (January 2007) more 
than 11 000 patients with more than 30 different medical entities have completed 
the first questionnaire.
Routine collection of HRQoL data as an indicator of treatment effectiveness 
proved to be feasible, requiring only a small amount of extra work and being 
potentially useful when combined with existing measures of hospital performance. 
Based on the costs (consisting of salaries, printing, copying, mailing, data recording, 
statistical consulting, meeting and travel costs, development of necessary software 
for patient administration) of the first 23 months (approximately €73 000) the cost 
per patient recruited was approximately €16 in the early phases of the project.
During the study the routine of sending out questionnaires could be 
automated in such a way that data collection required only a limited amount of 
extra work. Patients appeared to be generally satisfied with the fact that the hospital 
was interested in their well-being after treatment. No physician who was offered 
the chance to participate refused to allow data collection in the patient group he or 
she was responsible for. The attitudes of the nursing staff were generally positive 
towards data collection, although it caused some more extra work for some of 
them.
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5.3 Neurosurgery
Spinal surgery led to a statistically significant and clinically important improvement 
in mean HRQoL score in the studied patients (Table 2). At the three-month follow-
up the mean HRQoL score (on a 0-1 scale) had increased in a statistically significant 
manner both in the cervical group, and in the lumbar group (Table 2). Of the 15 
dimensions of the instrument, sleeping, usual activities, discomfort and symptoms, 
depression, distress, vitality and sexual activity had all improved significantly at 
the three-month follow-up in both groups (p < 0.05). In addition, moving and 
elimination improved statistically significantly (p < 0.05) in the lumbar group.
The mean (± SD) waiting time to operation was 68 days (± 57, range 0-388) 
for the cervical spine patients and 73 days (± 51, range 2-226) for the lumbar 
spine patients. In the 88 cervical spine patients that waited less than 60 days for 
the operation, the HRQoL score increased more (0.05 vs. 0.02) than in the 81 
patients that waited more than 60 days. A similar trend was also seen in lumbar 
spine patients, where the HRQoL score improvement was greater for those 43 
patients that waited less than 60 days than for those that waited longer (0.08 vs. 
0.05, respectively).
5.4 Cataract surgery
The mean HRQoL score had not statistically significantly increased six months 
after cataract surgery in the whole sample (Table 2). For further analysis, the 
cataract surgery patients were divided into three subgroups: group A: only one eye 
was operated on (n = 87), group B: both eyes were operated during the follow-up 
(n = 73), and group C: the first eye had been operated on earlier, prior to the study, 
and now the second eye was operated on (n = 59). Of the subgroups, only those 
who had had both eyes operated on (group B) showed a statistically significant (p 
< 0.001) improvement in the mean HRQoL (± SD) score from 0.80 (± 0.13) to 
0.83 (± 0.14). In group A, the HRQoL remained almost constant and in group C 
it deteriorated.
Of the 15 dimensions of the 15D instrument, only seeing improved significantly 
after the operation (p < 0.001). 17 % of patients reported having no preoperative 
difficulties in seeing and 47 % only minor difficulties (levels 1 and 2 of the five-
level seeing dimension). Their mean HRQoL score did not improve as a result of 
surgery. In patients reporting significant or major preoperative seeing problems 
(levels 3 to 5 of the seeing dimension), cataract surgery improved seeing (p < 
0.001) and distress (p = 0.036), and also had a statistically significant positive effect 
on the overall HRQoL score, which increased from 0.76 (± 0.14) to 0.78 (± 0.15) 
(p = 0.02).
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The correlation between the best-corrected visual acuity (expressed in LogMAR 
units) in the surgical eye and the subjective level of seeing (the seeing dimension of 
the HRQoL instrument) was poor (R = 0.17, p = 0.013). However, the visual acuity 
of the non-surgical eye correlated fairly well with the seeing dimension of the 15D 
instrument (R = 0.503, p < 0.001).
Compared to age- and gender-standardised general population, the cataract 
patients were preoperatively statistically significantly worse off on the dimensions 
of seeing, moving, sleeping, usual activities, depression and distress, but better off 
on the dimension of mental function. However, the overall HRQoL score did not 
differ in a statistically significant manner between the general population and the 
patients.
5.5 Hip and knee replacement surgery
The mean HRQoL score increased statistically significantly both in primary hip and 
in knee replacement patients from the preoperative status to 12 months (Table 2). In 
revision hip replacement patients, the mean increase was not statistically significant. 
Of the 15 dimensions of the 15D instrument, moving, usual activities, discomfort 
and symptoms, distress and vitality had improved statistically significantly in both 
primary replacement groups. The revision operation improved only the dimension 
of moving.
Those with a favourable result from primary THA (≥ 0.03 increase in the 
HRQoL score) were significantly younger than patients with a less optimal result. 
In primary TKA patients only shorter waiting time was significantly associated 
with favourable outcome.
The mean (±SD) HHS score of the primary THA patients before operation 
was 51 (±16) and that of the revision patients 47 (± 21). Twelve months after the 
operation the scores had increased to 81 (± 33) (p < 0.001) and 74 (± 35) (p = 
0.005), respectively. The KSS of the primary TKA patients before operation was 43 
(± 17) and had increased to 88 (± 27) at 12 months (p < 0.001).
5.6 Costs of interventions 
In cervical spine surgery the mean hospital costs were €3 356 and in lumbar spine 
surgery €3 493. In the cataract surgery group the mean hospital costs were €1 318 
in group A, €2 289 in group B and €1 323 in group C. The mean direct hospital 
costs of primary THA and TKA were fairly similar, but the mean cost of revision 
hip replacement operations was clearly higher (Table 2). 
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TAbLE 2. baseline characteristics and follow-up HRQoL and cost data. (*** denotes significant (p 
< 0.001) improvement in HRQoL score from baseline to follow-up). (THA = total hip arthroplasty; 
Revision THA = revision total hip arthroplasty; TKA = total knee arthroplasty; Cervical = cervical 
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(SD)
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5.7 Quality adjusted life-years gained by the  
 studied interventions
The mean QALY gain was largest in lumbar spine surgery 2.010 (± 2.958) followed 
by THA 1.302 (± 2.621), cervical spine surgery 1.210 (± 2.969), TKA 0.575 (± 
1.228), revision THA 0.215 (± 0.831), and cataract surgery 0.207 (± 1.002).
The mean discounted (5 %) QALY gain was largest for lumbar spine surgery 
followed by primary hip arthroplasty, cervical spine surgery, primary knee 
arthroplasty, revision hip arthroplasty, and cataract surgery (Figure 3).
In cervical spine surgery, the mean QALY gain in patients that waited less than 
60 days for the operation was clearly greater than in patients that waited more than 
60 days (1.68 vs. 0.70). A similar trend was also seen in lumbar spine patients, where 
the number of QALYs produced by the intervention (2.50 vs. 1.64) was higher for 
patients that waited for less than 60 days.
In the cataract patients, the mean QALY gain was clearly highest in those who 
had had both eyes operated on during the follow-up, 0.446 (± 1.197). In patients 
that had had only one eye operated on, it was 0.161 (± 0.942) and in those whose 
first eye had been operated on earlier it was -0.022 (± 0.742).
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FIgURE 3. Mean number of QALYs (discounted by 5%) gained by various surgical interventions 
(Cataract = cataract surgery; RevTHA = Revision total hip arthroplasty; TKA = total knee 
arthroplasty; Cervical = cervical spine surgery; THA = total hip arthroplasty; Lumbar = lumbar 
spine surgery).
5.8 Cost per quality-adjusted life year
The cost per QALY gained was €2 770 for cervical, and €1 740 for lumbar spine 
operations, respectively. Prolonged waiting for an operation doubled the cost per 
QALY. For cataract surgery the cost per QALY gained in the whole patient sample 
was €7 947. In subgroup A the cost per QALY was €8 210 and in subgroup B €5 130, 
respectively. In subgroup C the cost per QALY gained could not be established as 
the change in the HRQoL score was negative. In arthroplasty patients the cost per 
QALY gained was most favourable for primary THA (€6 710), followed by primary 
TKA (€14 000) and revision THA (€52 270) (Figure 4).
A comparison of all surgical interventions reported here reveals that both 
the undiscounted and the discounted (5 %) cost per QALY gained was lowest for 
lumbar spine surgery followed by cervical spine surgery, primary hip arthroplasty, 
cataract surgery, primary knee arthroplasty and revision hip arthroplasty (Figure 
4). However, in patients undergoing cervical or lumbar spine surgery, the cost per 
QALY was dependent on the waiting time for the operation, with longer waiting 
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Figure 4. Cost per QALY (undiscounted and discounted by 5 %) gained by five surgical 
interventions (Lumbar=lumbar spine surgery; Cervical=cervical spine surgery; THA=total hip 
arthroplasty; Cataract=cataract surgery; TKA=total knee arthroplasty; RevTHA=Revision total 
hip arthroplasty).
5.9 Sensitivity analyses
In cervical and lumbar spine patients (Study III) the cost per QALY gained was 
relatively robust against discounting and against both varying treatment cost or 
treatment effectiveness (HRQoL) within the 95 % confidence interval of the means 
observed in the study.
Similarly, in cataract patients (Study IV) the cost per QALY was in the one-way 
sensitivity analysis robust against discounting or varying the cost or effectiveness 
of treatment within the 95 % confidence interval observed in the study. However, 
using median values increased the cost per QALY substantially in the group of 
patients whose first eye had been operated on earlier.
In cataract patients, bootstrap simulation suggested that compared to no 
treatment, surgery was more costly and less effective in 46.4 % of simulated cases, 
and more costly and more effective in 53.6 % of simulated cases in subgroup A. The 
corresponding percentages were 37.9 % and 62.1 % in subgroup B and 51.1 % and 
48.9 % in subgroup C, respectively. Bootstrap sensitivity analysis also suggested 
that at a willingness to pay threshold of €20000 per QALY gained, the probability 
of cataract surgery being acceptable was 51.7 % in subgroup A, 59.0 % in subgroup 
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In the arthroplasty patients (Study V) the cost per QALY gained by primary 
THA ranged from €4 770 to €12 340, and that of primary TKA from €9 870 to €24 
020 depending on the assumptions used in the analysis. Revision hip replacement 
would produce a negative QALY gain precluding the calculation of cost per QALY, 
if effectiveness was at the lower boundary of the 95 % CI of the mean observed in 
the study. In contrast, if the effectiveness of revision hip replacement were at the 
higher boundary of the 95 % CI of the mean observed, the cost per QALY would –
although still being rather high – go down to €19 860.
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6	 Discussion
Scarce resources are a reality in secondary health care and will, at least in the long run, 
necessitate prioritisation between different patient groups and interventions. Such 
prioritisation, if it is to be fair and balanced, is not possible without a systematic, 
continuous evaluation of the effectiveness and costs of various treatments. The main 
aim of this study was to test the feasibility of an approach to the routine collection 
of cost-effectiveness data and to establish the potential benefits such a system could 
provide. A similar approach has earlier been used in Finland in two pilot studies 
(Blom-Lange 1998; Kukkonen 2005). Furthermore, numerous studies from other 
parts of the world have evaluated the cost-utility of the treatment of individual 
diseases. However, this is to our knowledge the first large-scale experiment aimed 
at evaluating the cost-effectiveness of several medical interventions side-to-side.
The approach taken in this study turned out to be feasible. The estimation 
of treatment effectiveness using systematic HRQoL assessments did not require 
significant extra efforts or investments and the attitudes of the hospital personnel 
were generally positive towards the project. The latter, for instance, is exemplified 
by the fact that a great majority (92 %) of the orthopaedic patients were offered the 
15D questionnaire despite the fact that this meant some extra work for the nurses 
responsible for patient care. No physician offered the chance to participate refused 
to allow data collection in the clinical specialty he/she is responsible for. In all cases, 
the initiation of data collection naturally required personal communication with 
those responsible for distribution of the first questionnaires, and in some cases 
continuous attention and motivation was needed to ensure successful continuation 
of the data collection.
Patients also appreciated the somewhat unusual event that the hospital 
showed interest in their well-being, indicated by the fairly high response rate to the 
first questionnaire compared to surveys in general. Even the response rate for the 
second questionnaire was good at around 80 %. 
To sufficiently automate data collection, even though it remained paper-
based throughout the initial phase of the project, some investments in software 
solutions were necessary at the beginning of the project. To enable mailing of the 
questionnaires, a Microsoft Access® database was tailored according to the needs 
of the project, which allowed sufficient automation so that mailing could easily be 
handled by one person alone. However, to reduce the amount of human resources 
needed, large scale data collection in the future should, at least in part, be internet-
based so that patients can enter the data directly into a database.
The merging of effectiveness data with cost data and information on the 
treatments was unproblematic in the Ecomed® database. However, in cases where 
individual patients had been treated multiple times during the follow-up, it was 
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sometimes difficult to ascertain to which treatment the effectiveness data were 
connected. Similarly, it is also virtually impossible to tell the effect of a single 
intervention on the change in HRQoL if the patient has received treatments for 
more than one illness during the follow-up. Some of the problems can be overcome 
by manually checking that the effectiveness data are linked to the right treatment 
during the follow-up period, but this requires extra work and is feasible only 
when the study sample size is small. It does not, however, solve the problem of 
establishing how much each treatment has contributed to the change in HRQoL. 
In large patient samples, hand checking may not be that important as some deviant 
patients easily disappear into the mass if thousands of patients are studied and thus 
do not bias the results in a significant way.
The primary strength of the current economic analysis is that it is based 
on real world patients of the HUCH receiving scheduled surgical treatment 
under currently accepted practices and indications. Other published economic 
analyses have mostly been based on clinical trial data, which may not reflect the 
situation observed under routine circumstances. Our results, therefore, reflect 
the true effectiveness of interventions instead of merely their efficacy. Admittedly, 
randomised controlled trials estimating the efficacy of various new treatments 
are also essential when considering whether to introduce a new treatment or not. 
However, results from an RCT represent at best the efficacy of an intervention, not 
its effectiveness (Gold et al. 1996). Subsequent effectiveness data are thus essential if 
decisions on the allocation of resources are to be as objective and comprehensive as 
possible. Consequently, there will always be a need for both types of methodologies 
– that of RCT and real-life studies – to be carried out sequentially and if necessary, 
repeatedly over time. 
Although QALYs gained are considered an important measure of effectiveness 
of health care, the number of studies reporting QALYs based on actual measurement 
of patients’ HRQoL is still fairly limited. Such studies, however, are urgently needed 
to ensure that allocation of health care resources is based on scientific evidence 
on the value of various interventions regarding their ability to produce societal 
welfare.
A strength of the QALY approach used in this study is the fact it reflects 
patients’ own assessment of their health status. The key issue in assessing the 
effectiveness of secondary health care should be the patient’s own evaluation: how 
they feel that the intervention has affected their HRQoL. Traditionally, the providers 
of treatments have assessed the effectiveness of interventions by using provider-
oriented outcomes. Such an approach is, however, prone to lead to subjective and 
biased assessments. Even though health care professionals certainly are aware of 
the clinical nature of a disease and the burden it can cause for their patients, it is 
unlikely that they – having never experienced the disease themselves – would really 
be able to judge patients’ HRQoL adequately. Furthermore, the clinical outcomes 
used to evaluate effectiveness are usually disease- or at best specialty-specific, and 
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do not allow a comparison of treatment results across different clinical specialties. 
Therefore, studies based on real patient data are arguably of much more value for 
the decision-maker pondering over allocation of resources.
For instance, regarding cataract surgery, the evaluation of visual acuity 
or visual quality of life alone, although important, serves only the purpose of a 
health status measure, and is not sufficient to reflect the true HRQoL of patients. 
According to some recent studies the impact of seeing on generic HRQoL may 
have been exaggerated in the past. Although some studies have established a 
relationship between difficulties in seeing and HRQoL, others have indicated that 
visual impairment does not affect generic HRQoL as much as generally assumed. 
For instance in patients with unilateral visual impairment, a deteriorated HRQoL 
– as measured by the SF-36 instrument – was found only in those moderately to 
severely affected (Chia et al. 2004). Espallargues et al. (2005) have reported that 
for patients with age-related macular disease, even severe visual impairment was 
not reflected in patients’ own assessment of life and satisfaction measured using 
several HRQoL instruments. Furthermore, the disease-specific VF-14 score was 
found to correlate only moderately with visual acuity in the better eye (Steinberg 
et al. 1994). 
The cost per QALY gained for knee arthroplasty was two-fold compared 
to hip replacement. For revision hip arthroplasty the cost per QALY was clearly 
higher than for the studied primary interventions. The latter finding stresses the 
importance of the primary operation and the choice of the best possible implant 
material so that revision operations can be avoided as far as possible.
This study showed that there is great variation in the cost-utility of various 
interventions performed in a real-world setting even when only common, widely 
accepted interventions are considered. Spinal surgery turned out to be the most 
cost-effective intervention regarding the cost per QALY gained. On the other hand, 
spinal disorders are usually self-limiting and most patients recover with time 
also without surgery. To establish the real incremental cost-effectiveness of spinal 
surgery comparative studies employing conservative treatment as a control would 
be necessary.
Lansingh et al. (2007) reported in a recent meta-analysis that the cost-utility 
of cataract surgery varies greatly worldwide. In their opinion, that is mainly a 
consequence of differing methods and time frames used for assessing the benefits 
of the intervention. According to their results, cataract surgery is comparable to 
hip arthroplasty in respect of cost-effectiveness, and more cost-effective than knee 
arthroplasty or implantation of a defibrillator. In our material, cataract surgery 
was more expensive regarding the cost per QALY than seen in many earlier studies. 
One explanation for this might be the mixed patient material of a university clinic 
with many patients suffering from secondary ophthalmic problems in addition 
to cataract. Another reason for the unexpectedly small increase in HRQoL after 
cataract surgery may be that two thirds of the patients reported only minimal 
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preoperative subjective difficulties in seeing despite objective evidence of poor 
visual acuity in the operated eye. The small HRQoL gain observed as the result of 
routine cataract surgery was confined mainly to an improvement in seeing only. 
In patients suffering from significant or major preoperative difficulties in seeing, 
the HRQoL gain was more encouraging. It is possible that cataract operations have 
earlier been performed at a later stage of the disease and on patients that have 
suffered more from the detrimental consequences, such as injuries (Stenevi et al. 
2000) due to poor visual acuity. Consequently, the gain achieved by the operation 
might also have been larger in earlier studies. From our current results it is clear, 
however, that to justify resource use on cataract surgery, the patient has to have 
definitive medical indications for the surgery or its cost-effectiveness needs to be 
proven with clear paybacks in the form of improved quality of life. 
In addition to providing the means for comparing the cost-effectiveness of 
interventions performed in different medical specialties, our approach also makes 
it possible for surgeons and surgical units within one specialty to compare their 
performance with those of their colleagues, and thus hopefully improve their 
practices and generate clinical benefits for the patients. When generalizing these 
results to other hospital districts, one has to be cautious because of possible 
variation in costs of treatment. 
Further research is urgently required to give more comparators for analysis 
and better evidence as a background for decisions. This calls for continuous 
monitoring of the cost-utility of various interventions to optimise health care 
spending. Changes to the delivery and organisation of health services should be 
evaluated before they are widely implemented. Too much momentum may lead 
to an inappropriate implementation of change before an evaluation is complete 
(McDonnell et al. 2006).
Cost-effectiveness analysis is not the only circumstance where HRQoL 
assessments are useful. They can also be used to refine patient selection, to evaluate 
which patient groups gain most from interventions, and to compare different 
service providers in terms of effectiveness of care. 
6.1 Limitations of the study
Cost data used for the analyses covered only the relevant specialty-related costs and 
not the costs of primary health care and outpatient medication or productivity 
costs. Ideally the perspective for an economic analysis should be societal and take 
into account all types of costs, not only direct hospital costs. However, Brouwer et 
al. (2006) have suggested that it may be useful to adopt a two-perspective approach 
as a standard, presenting one cost-effectiveness ratio following a strict health-care 
perspective and one following the common societal perspective. 
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In at least two of the studied interventions, the costs of hospital treatment 
make up the bulk of the direct total costs of treatment, as there is no known effective 
cure for cataract or osteoarthritis of the hip or knee other than surgery. In the case 
of back surgery this not as evident and it is true that a more detailed analysis of 
the costs of conservative treatment would be useful, but was not within the scope 
of the current study. Thus the method of using cost data readily available from the 
hospital accounting system, instead of tediously collecting data from individual 
patients, can be defended, and is in a trial that involves several thousand patients 
the only feasible possibility as yet to acquire reasonably reliable cost data. In the 
future, however, emphasis needs to be put on efforts to develop methods to reliably 
estimate the costs of the whole treatment chain (including at least the costs of 
primary care and those of medication) by for instance combining existing registers 
already containing the necessary information. A nationwide standardised electronic 
system for routine recording of resource use and HRQoL data at all levels of the 
health care system would be of immense importance for more comprehensive cost 
data collection and routine assessment of cost-effectiveness of treatment.  
It is possible that the use of a societal perspective could affect some of the 
conclusions of this study and certainly would have some impact on the cost 
per QALY figures. The extent of the impact is, however, impossible to establish 
presently. Already ongoing studies may answer some of these questions in the 
future. Preliminary results from such studies employing arthroplasty patients 
similar to those enrolled in our study indicate that the use of additional health 
care services, such as home care or rehabilitation, is in arthroplasty patients fairly 
limited and thus do not have a major effect on the overall health care costs of an 
arthroplasty patient (Hirvonen et al. 2006).
The health economic analytical approach used in this study can be criticised 
for making some fairly straightforward assumptions. One of them is the 
assumption that the studied interventions do not affect the length of life. Also the 
lack of multivariate analysis to handle the confounding factors that may be present 
in routine-styled settings can be criticised. On the other hand, the relevance of 
some economic evaluations has been criticised for the lack of real world data 
and poor generalisability of results (Guidelines for the Economic Evaluation of 
Health Technologies, 2006), which may especially be a problem in health economic 
modelling often based on vaguely defined data. Nonetheless, this is probably the first 
endeavour to evaluate the cost-utility of a large part of secondary health care and, 
although the methods of data collection and analysis certainly need to be refined in 
the future, it provides a sound, pragmatic basis for the start of continuous, routine 
monitoring of the cost-utility of secondary health care.
The time horizon of data collection ranged in our study from three to 
12 months. Regarding the interventions studied here, this can be considered 
sufficient as all of the studied interventions can be expected to have produced 
maximal benefit by the time of repeat data collection. For some other health care 
 STAKES 2007
Routine Measurement of Health-Related Quality of Life in Assessing 
Cost-Effectiveness in Secondary Health Care
interventions this may not always be true and the timing of data collection needs 
to be adjusted individually to meet the needs of specific research questions in other 
fields of medicine.
Our QALY calculations are based on the simplistic assumption that the 
improvement in HRQoL is permanent. This is of course not always true as HRQoL 
is known to deteriorate with advancing age while other concurrent diseases may 
also affect it negatively. In the future, longer follow-up times would be needed to 
make the analyses more reliable. In some cases more refined analyses using health 
economic modelling using registry data –for example the number of re-interventions 
in orthopaedics – may certainly be necessary. The HRQoL data collected in our 
experiment provides a sound basis for such analyses. On the other hand, health 
economic modelling is always based on at least some assumptions regarding the 
natural course of the studied disease and is thus also subject to uncertainties. Our 
results, by contrast, reflect the true everyday effectiveness accomplished in health 
care. Although our findings must be interpreted with care, they represent, in our 
opinion, as valid an approach to defining the cost-utility of secondary care as health 
economic modelling.
6.2 Future perspectives
Although the results of the project provide a sound basis for comparing the cost-
utility of various interventions, another question is whether they really influence 
health care decision-making. There are indications from earlier studies that feedback 
of good quality effectiveness data is not always able to influence for instance the 
decisions of practicing surgeons (Wright et al. 2002). A future objective should 
thus be to study the use of the cost-utility data produced in the project, and to 
establish whether such data really are able to influence medical decision making in 
a significant manner.
Another future priority should be to study whether the observed poor 
outcome in some patients can be predicted by pre-treatment HRQoL dimensions 
or available clinical variables. These analyses can partly be performed using already 
collected data; there is a need to also use patient registers. In the future, methods 
based on artificial intelligence to predict treatment outcomes on a case-by-case 
basis may replace current approaches based mainly on mean data obtained from 
groups of patients. Such data could help tailor treatment approaches according to 
the needs and prognoses of individual patients (Ryynänen 2005).
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7	 Conclusions
On the basis of the present study, the following conclusions can be drawn.
1. Although QALYs are considered an important measure of effectiveness of health 
care, the number of studies in which QALYs are based on actual measurements 
of patients’ HRQoL with a valid method remains fairly limited.
2. Routine collection of HRQoL data as an indicator of treatment effectiveness is 
feasible, requires only a small amount of extra work, and is potentially useful 
when combined with existing measures of hospital performance.
3. Spinal surgery led to a statistically significant and clinically important 
improvement in HRQoL and the cost per QALY gained was reasonable; 
however a prolonged delay in the surgical intervention led to an approximate 
doubling of the cost per QALY gained by the treatment.
4. Cataract surgery had only a minor effect on HRQoL in most of the patients 
and the improvement was confined mostly to patients whose both eyes were 
operated on during the study period. The cost of cataract surgery per QALY 
was much higher than previously reported.
5. Primary hip and knee replacement were both effective in improving the mean 
HRQoL score in our patients. By contrast, the improvement in HRQoL after 
revision hip arthroplasty was fairly small and statistically insignificant. The cost 
per QALY gained from knee replacement is twice that of hip replacement.
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